Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × talimogene laherparepvec × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 17 Sarcoma 9 Breast 7 Gastrointestinal 4 Lymphoid 3 Head & Neck 2 Thoracic 1 Gynecologic 1 CNS 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 504 Carboplatin 465 Cisplatin 306 Bevacizumab 220 pembrolizumab 203 Gemcitabine 130 Cyclophosphamide 113 Topotecan 109 olaparib 106 liposomal doxorubicin 104 Radiotherapy 98 Taxes 96 Docetaxel 85 Brachytherapy 82 Doxorubicin 77 Drug Therapy 71 niraparib 69 Nivolumab 65 Magnetic Resonance Spectroscopy 61 Specimen Handling 56 Biopsy 53 fludarabine 52 Hyperthermic Intraperitoneal Chemotherapy 46 Letrozole 45 Filgrastim 44 durvalumab 43 Platinum 41 Oxaliplatin 40 Radiation 39 Immunoglobulin G 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03663712 2024-11-20

TEMPO

Duke University

Phase 1 Completed

28 enrolled 10 charts

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡